Skip to content
Screener

Organon OGN Return on equity

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%—
Amgen logo
AmgenAMGN
91.5%-7.7pp
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
2.9%-2.3pp
Biogen logo
BiogenBIIB
4.8%-4.3pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Opko Health logo
Opko HealthOPK
-5.9%-2.1pp

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Calculated from Organon’s reported figures.

net income/total stockholders equity=71.6%

Based on trailing twelve months.

The source filing: Organon’s 10-Q, filed November 10, 2025. Open the filing →

Filed
Nov 10, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0001628280-25-050795

FAQ

What is Organon's return on equity?
Organon (OGN) reported return on equity of 71.6% in Q3 2025.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Organon's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude